Medicinal plants and compounds for chronic bronchitis treatment: efficacy and action mechanisms

Wei Ding, Danni Chen, Jiawang Li, Yan Wang, Xiangyun Chen, Yihe Xu, Zhen Yang, Zhenhong Liu, Hongxia ZhaoFrontiers in Pharmacology 2025 · DOI

TL;DR

Chronic bronchitis (CB) is a persistent inflammatory lung disease with limited treatment options. This review synthesizes evidence from preclinical animal studies, revealing that numerous medicinal plants and their derived compounds exhibit significant anti-inflammatory, antioxidant, and mucus-reducing effects. These natural agents show promise for developing novel CB therapies by targeting key molecular pathways involved in the disease.

What Problem Does This Paper Address?

Chronic bronchitis (CB) is a common, yet challenging, respiratory condition characterized by persistent inflammation, oxidative stress, and excessive mucus production. It's a major component of Chronic Obstructive Pulmonary Disease (COPD), affecting millions globally and contributing to significant mortality. Current treatments, while helpful for symptom management, often fail to reverse the underlying disease progression. This leaves a critical unmet need for more effective therapeutic strategies. While traditional medicine has long utilized plants for respiratory ailments, a systematic understanding of their efficacy and the underlying mechanisms against CB is lacking. This paper aims to bridge that gap by consolidating and analyzing the preclinical evidence for medicinal plants and compounds in treating CB.

Methods

This study employed a systematic review methodology, adhering to the PRISMA guidelines and a prospectively registered protocol (PROSPERO ID: CRD42024588912). The researchers conducted an extensive literature search across eight major databases (PubMed, Scopus, Embase, Web of Science, VIP, Wan-fang, SinoMed, and China National Knowledge Infrastructure) to identify relevant studies. The search strategy combined Medical Subject Headings (MeSH) terms and free-text phrases related to CB, plants, herbs, and phytochemicals.

Inclusion and exclusion criteria were strictly defined using the PICOS framework:

  • P (Patients): Chronic bronchitis (CB)
  • I (Intervention): Medicinal plant extracts and plant-derived compounds
  • C (Comparison): Comparative control group
  • O (Outcome): Anti-inflammatory potency
  • S (Study type): In vivo animal studies (rats, mice, or guinea pigs)

Studies were excluded if they were theses, editorials, reviews, clinical studies, theoretical research, case reports, conference proceedings, book chapters, letters, or grey literature not meeting the PICOS criteria. Two independent reviewers assessed the identified literature for eligibility based on titles, abstracts, and full-text articles. Methodological rigor of the included animal studies was assessed using the SYRCLE's risk of bias tool.

Datasets

Not discussed in the paper. The paper focuses on a systematic review of existing literature, not on the creation or use of new datasets for training or evaluation.

Key Insights and Ideas

  • Multi-targeted Natural Agents: The review highlights that many medicinal plants and their compounds don't just target one aspect of CB but offer a multi-pronged approach, addressing inflammation, oxidative stress, and mucus production simultaneously. This is a key advantage over single-target drugs.
  • Key Molecular Pathways Identified: The research pinpoints several crucial signaling pathways that these natural agents modulate, including NF-κB, PI3K/AKT/mTOR, TLR4, MAPK, and Nrf2. Understanding these pathways provides a mechanistic basis for their therapeutic effects.
  • Ursolic Acid as a Promising Candidate: Among the many compounds investigated, Ursolic acid stands out as a particularly promising clinical candidate due to its broad-spectrum activity and effectiveness across multiple preclinical models.
  • Bridging Traditional and Modern Medicine: The review effectively bridges traditional medicinal knowledge with modern scientific validation, providing a solid foundation for the development of new, plant-derived CB therapies.
  • Risk of Bias in Preclinical Studies: While many studies showed positive results, the review acknowledges limitations in the methodological quality of preclinical research, particularly concerning randomization and blinding, which could impact the certainty of the findings.

Key Results

The systematic review identified 13 medicinal plants and 19 compounds demonstrating significant anti-inflammatory activity against CB in preclinical models. Furthermore, 8 plants and 12 compounds showed additional beneficial effects, including antioxidant, anti-mucus, and potential bronchodilatory properties.

The underlying mechanisms of action primarily involved the modulation of key inflammatory and cellular signaling pathways:

  • NF-κB pathway: Inhibited by compounds like quercetin, mangiferin, and ursolic acid, leading to reduced inflammatory mediators.
  • PI3K/AKT/mTOR pathway: Targeted by scutellarin and polydatin, contributing to reduced inflammation and disease progression.
  • TLR4 pathway: Modulated by Lysionotus pauciflorus Maxim, offering protection against lung injury.
  • MAPK pathway: Inhibited by ursolic acid, ameliorating lung inflammation.
  • Nrf2 pathway: Activated by punicalagin and others, enhancing antioxidant capacity and anti-inflammatory effects.

Specific examples of effective plants and compounds include:

  • Aconitum septentrionale: Showed dose-dependent therapeutic effects comparable to a positive control drug.
  • Ajuga decumbens: Alleviated bronchial obstruction and reduced inflammatory markers.
  • Atalantia buxifolia: Improved body weight and reduced inflammation.
  • Eucalyptus globulus Labill. oil: Reduced inflammatory cell counts and mucin expression.
  • Ursolic acid: Demonstrated dose-dependent attenuation of inflammation and oxidative stress.

Limitations and Future Work

The authors acknowledge several limitations:

  • Methodological Quality: Many included studies were of medium quality, with potential biases due to incomplete blinding and randomization procedures.
  • Lack of Clinical Validation: The findings are primarily based on preclinical animal studies. There is a significant need for validation in high-quality randomized controlled trials (RCTs) in human patients.
  • Pharmacokinetics and Dosing: Data on the pharmacokinetics, optimal dosing, and long-term safety profiles of these natural agents in humans are largely missing.

Future research should prioritize:

  • Well-designed Phase I/II clinical trials to establish safety and preliminary efficacy in CB patients.
  • Enhancing the bioavailability of poorly soluble compounds.
  • Standardizing extraction protocols for consistent product quality.
  • Exploring combination therapies with existing standard treatments.
  • Further investigation into the safety and toxicity of these natural products.

Summary updated

Abstract

This review represents the first comprehensive synthesis of experimentally verified efficacy and mechanisms associated with medicinal plants and compounds in CB treatment. Preclinical animal studies have confirmed the therapeutic benefits of these natural agents in alleviating CB symptoms, establishing a solid foundation for novel drug development and underscoring their considerable translational potential.
BibTeX
@inproceedings{ding2025medicinal,
  author = {Wei Ding and Danni Chen and Jiawang Li and Yan Wang and Xiangyun Chen and Yihe Xu and Zhen Yang and Zhenhong Liu and Hongxia Zhao},
  title = {{Medicinal plants and compounds for chronic bronchitis treatment: efficacy and action mechanisms}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2025.1674079},
}
Figure